Article ID Journal Published Year Pages File Type
9005574 Clinical Therapeutics 2005 14 Pages PDF
Abstract
IBS-specific agents offer an opportunityfor patients with IBS to achieve global symptom improvement. However, when weighing the costs and potential risks against the potential benefits, clinicians should consider the nature and severity of the patient's symptoms, the degree of functional impairment, and the presence of psychosocial comorbidities.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, ,